In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6366-6371

  Mataraci, Emel ^a   Dosler, Sibel ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; AZITHROMYCIN; CECROPIN A (1-7) MELITTIN A (2-9) AMIDE; CIPROFLOXACIN; DAPTOMYCIN; INDOLICIDIN; LINEZOLID; NISIN; TEICOPLANIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOFILM; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CATIONS; DRUG COMBINATIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; NISIN; PEPTIDES;

EID: 84869211892     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01180-12     Document Type: Article

References (34)

1. Bordi C, de Bentzmann S. 2011. Hacking into bacterial biofilms: a new therapeutic challenge. Ann. Intensive Care 1:19. doi:10.1186/2110-5820-1-19.
2. Cao Y, et al. 2010. Design, recombinant expression, and antibacterial activity of the cecropins-melittin hybrid antimicrobial peptides. Curr. Microbiol. 61:169-175.
3. Ceri H, et al. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
4. Chen L, Wen YM. 2011. The role of bacterial biofilm in persistent infections and control strategies. Int. J. Oral Sci. 3:66-73.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; 2nd informational supplement. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Dean SN, Bishop BM, van Hoek ML. 2011. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol. 11:114. doi:10.1186/1471-2180-11-114.
8. de la Fuente-Núñez C, et al. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob. Agents Chemother. 56:2696-2704.
9. Dempsey CE, Hawrani A, Howe RA, Walsh TR. 2010. Amphipathic antimicrobial peptides from biophysics to therapeutics. Protein Pept. Lett. 17:1334-1344.
10. Donlan RM. 2001. Biofilm formation: a clinically relevant microbiological process. Clin. Infect. Dis. 33:1387-1392.
11. Durham-Colleran MW, Verhoeven AB, van Hoek ML. 2010. Francisella novicida forms in vitro biofilms mediated by an orphan response regulator. Microb. Ecol. 59:457-465.
12. Falla TJ, Karunaratne DN, Hancock RE. 1996. Mode of action of the antimicrobial peptide indolicidin. J. Biol. Chem. 271:19298-19303.
13. Ghannoum M, O'Toole GA. 2004. Microbial biofilms. ASM Press, Washington, DC.
14. Giacometti A, Cirioni O, Greganti G, Quarta M, Scalise G. 1998. In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Antimicrob. Agents Chemother. 42:3320-3324.
15. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
16. Kardas-Sloma L, et al. 2011. Impact of antibiotic exposure patterns on selection of community-associated methicillin-resistant Staphylococcus aureus in hospital settings. Antimicrob. Agents Chemother. 55:4888-4895.
17. Kharidia R, Liang JF. 2011. The activity of a small lytic peptide PTP-7 on Staphylococcus aureus biofilms. J. Microbiol. 49:663-668.
18. LaPlante KL, Mermel LA. 2009. In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains. Antimicrob. Agents Chemother. 53:3166-3169.
19. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents: approved guideline M26-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Okesola AO. 2011. Community-acquired methicillin-resistant Staphylococcus aureus: a review of literature. Afr. J. Med. Med. Sci. 40:97-107.
21. Otto M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol. 322:207-228.
22. Overhage J, et al. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76:4176-4182.
23. Pillai SK, Moellering RC, Jr, Eliopoulos GM. 2005. Antimicrobial combinations, p 365-440. In Lorian V (ed), Antibiotics in laboratory medicine, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
24. Pompilio A, et al. 2011. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32:1807-1814.
25. Rosenthal VD, et al. 2012. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am. J. Infect. Control 40:396-407.
26. Ross AC, Vederas JC. 2011. Fundamental functionality: recent developments in understanding the structure-activity relationships of lantibiotic peptides. J. Antibiot. 64:27-34.
27. Selsted ME, et al. 1992. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J. Biol. Chem. 267:4292-4295.
28. Tang HJ, et al. 2012. In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms. J. Antimicrob. Chemother. 67:944-950.
29. Wade D, et al. 1992. Antibacterial peptides designed as analogs or hybrids of cecropins and melittin. Int. J. Pept. Protein Res. 40:429-436.
30. Willey JM, Van der Donk WA. 2007. Lantibiotics: peptides of diverse structure and function. Annu. Rev. Microbiol. 61:477-501.
31. Wootton M, et al. 1995. A critical assessment of the agar dilution checkerboard technique for studying in-vitro antimicrobial interactions using a representative beta-lactam, aminoglycoside and fluoroquinolone. J. Antimicrob. Chemother. 35:569-576.
32. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55.
33. Yeung AT, Gellatly SL, Hancock RE. 2011. Multifunctional cationic host defence peptides and their clinical applications. Cell. Mol. Life Sci. 68:2161-2176.
34. Zendo T, Yoneyama F, Sonomoto K. 2010. Lactococcal membrane- permeabilizing antimicrobial peptides. Appl. Microbiol. Biotechnol. 88:1-9.